JPH03500049A - ストレス、不安および発作活性の緩和のための組成物および方法 - Google Patents

ストレス、不安および発作活性の緩和のための組成物および方法

Info

Publication number
JPH03500049A
JPH03500049A JP1500671A JP50067189A JPH03500049A JP H03500049 A JPH03500049 A JP H03500049A JP 1500671 A JP1500671 A JP 1500671A JP 50067189 A JP50067189 A JP 50067189A JP H03500049 A JPH03500049 A JP H03500049A
Authority
JP
Japan
Prior art keywords
group
alicyclic
straight chain
aromatic group
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1500671A
Other languages
English (en)
Japanese (ja)
Inventor
ジー、ケルビン・ダブリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPH03500049A publication Critical patent/JPH03500049A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP1500671A 1987-08-25 1988-08-24 ストレス、不安および発作活性の緩和のための組成物および方法 Pending JPH03500049A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8936287A 1987-08-25 1987-08-25
US089,362 1987-08-25

Publications (1)

Publication Number Publication Date
JPH03500049A true JPH03500049A (ja) 1991-01-10

Family

ID=22217242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1500671A Pending JPH03500049A (ja) 1987-08-25 1988-08-24 ストレス、不安および発作活性の緩和のための組成物および方法

Country Status (5)

Country Link
EP (1) EP0382790A4 (da)
JP (1) JPH03500049A (da)
AU (1) AU609927B2 (da)
DK (1) DK48790A (da)
WO (1) WO1989002272A1 (da)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005179370A (ja) * 1993-05-24 2005-07-07 Purdue Pharma Lp 睡眠を誘導するための方法および組成物
JP2021513532A (ja) * 2018-02-11 2021-05-27 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ステロイド系誘導体モジュレーター、その製造方法及び応用
JP2022130546A (ja) * 2011-10-14 2022-09-06 セージ セラピューティクス， インコーポレイテッド ３，３－二置換１９－ノルプレグナン化合物およびその使用
JP2023040180A (ja) * 2011-09-08 2023-03-22 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DE602006020353D1 (de) 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE538830A (da) * 1954-10-21
FR1549153A (da) * 1962-06-15 1968-12-13
US3558673A (en) * 1966-10-29 1971-01-26 Ormonoterapia Richter Spa 10beta-amino-19-nor-pregnanes and method for the preparation thereof
DE2438020A1 (de) * 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
FR2414514A1 (fr) * 1978-01-11 1979-08-10 Roussel Uclaf Nouveaux derives steroides 17aaryle ou aheteroaryle, leur procede de preparation et leur application comme medicament
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
US4605649A (en) * 1983-02-22 1986-08-12 Liehr Joachim G Method of treatment of estrogen deficiency disease
FI83087C (fi) * 1984-05-16 1991-05-27 Schering Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara estriol-3,17-diestrar.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005179370A (ja) * 1993-05-24 2005-07-07 Purdue Pharma Lp 睡眠を誘導するための方法および組成物
JP2023040180A (ja) * 2011-09-08 2023-03-22 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
JP2022130546A (ja) * 2011-10-14 2022-09-06 セージ セラピューティクス， インコーポレイテッド ３，３－二置換１９－ノルプレグナン化合物およびその使用
JP2021513532A (ja) * 2018-02-11 2021-05-27 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ステロイド系誘導体モジュレーター、その製造方法及び応用
JP2024045458A (ja) * 2018-02-11 2024-04-02 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ステロイド系誘導体モジュレーター、その製造方法及び応用

Also Published As

Publication number Publication date
EP0382790A4 (en) 1991-03-27
AU609927B2 (en) 1991-05-09
DK48790A (da) 1990-04-25
EP0382790A1 (en) 1990-08-22
WO1989002272A1 (en) 1989-03-23
DK48790D0 (da) 1990-02-23
AU2828389A (en) 1989-04-17

Similar Documents

Publication Publication Date Title
JPH06505958A (ja) 脳興奮性調節のための方法、組成物および化合物
JPH03500049A (ja) ストレス、不安および発作活性の緩和のための組成物および方法
JP5289281B2 (ja) Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド
JP3710470B2 (ja) アンドロスタン及びプレグナン系列の構成要素によるｇａｂａ受容体のアロステリック修飾のための方法、組成物及び化合物
Paul et al. Neuroactive steroids
Kaminska et al. Dehydroepiandrosterone sulfate (DHEAS) counteracts decremental effects of corticosterone on dentate gyrus LTP. Implications for depression
CN103764151B (zh) Cb1受体拮抗剂
JPH10509458A (ja) Ｇａｂａレセプターをアロステリック調節するためのアンドロスタンおよびプレグナン系列
US5763431A (en) Method for regulating neuropeptide hormone secretion
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
Yu et al. The endogenic neurosteroid system and its role in the pathogenesis and therapy of mental disorders
Bowers et al. Biochemical and behavioral effects of steroids on GABAA receptor function in long-and short-sleep mice
Watanabe et al. Stimulation of gastric acid secretion by progesterone metabolites as neuroactive steroids in anesthetized rats
Mosbach et al. Early pathologic and biochemical changes in rabbits fed dihydrocholesterol
Dubrovsky et al. Electrophysiological Studies of Steroid Action
Merk GLUCOCORTICOSTEROIDS AND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: MECHANISMS OF ACTION AND